TWI238824B
(en)
|
2001-05-14 |
2005-09-01 |
Novartis Ag |
4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
|
JP4563171B2
(ja)
|
2002-05-24 |
2010-10-13 |
シェーリング コーポレイション |
中和ヒト抗igfr抗体
|
GB0226370D0
(en)
*
|
2002-11-12 |
2002-12-18 |
Novartis Ag |
Organic compounds
|
US7579157B2
(en)
*
|
2003-07-10 |
2009-08-25 |
Hoffmann-La Roche Inc. |
Antibody selection method against IGF-IR
|
WO2005011598A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
CA2533861A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Novartis Ag |
Combinations comprising staurosporines
|
ATE525377T1
(de)
*
|
2003-10-15 |
2011-10-15 |
Osi Pharm Inc |
Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
|
US7326567B2
(en)
|
2003-11-12 |
2008-02-05 |
Schering Corporation |
Plasmid system for multigene expression
|
AR046639A1
(es)
|
2003-11-21 |
2005-12-14 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti- igfr1
|
ES2368741T3
(es)
*
|
2004-02-25 |
2011-11-21 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
|
AP2139A
(en)
|
2004-04-02 |
2010-08-21 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
|
NZ549925A
(en)
|
2004-04-07 |
2010-08-27 |
Novartis Ag |
Inhibitors of IAP
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
CA2575808A1
(en)
|
2004-08-02 |
2006-02-16 |
Osi Pharmaceuticals, Inc. |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
JP2008521907A
(ja)
|
2004-12-03 |
2008-06-26 |
シェーリング コーポレイション |
抗igf1r治療について患者を予め選択するためのバイオマーカー
|
BRPI0608777A2
(pt)
*
|
2005-04-15 |
2010-01-26 |
Schering Corp |
métodos para tratamento ou prevenção de cáncer, bem como uso de inibidores de igf1r na preparação de composições farmacêuticas
|
US8859581B2
(en)
*
|
2005-04-25 |
2014-10-14 |
Merck Patent Gmbh |
Azaheterocyclic compounds as kinase inhibitors
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
US20060281768A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Gaul Michael D |
Thienopyrimidine and thienopyridine kinase modulators
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
NZ564098A
(en)
|
2005-06-15 |
2010-04-30 |
Schering Corp |
Anti-IGF1R antibody formulations
|
US7566721B2
(en)
*
|
2005-08-08 |
2009-07-28 |
Osi Pharmaceuticals, Inc. |
Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
|
ES2374450T3
(es)
|
2005-09-20 |
2012-02-16 |
OSI Pharmaceuticals, LLC |
Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
|
GB0520164D0
(en)
*
|
2005-10-04 |
2005-11-09 |
Novartis Ag |
Organic compounds
|
CA2626623C
(en)
|
2005-10-18 |
2016-08-30 |
Janssen Pharmaceutica N.V. |
Method of inhibiting flt3 kinase
|
JP5116687B2
(ja)
*
|
2005-11-02 |
2013-01-09 |
バイエル・ファルマ・アクチェンゲゼルシャフト |
がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
WO2007075554A2
(en)
*
|
2005-12-19 |
2007-07-05 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
US8575164B2
(en)
*
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
DE102006016426A1
(de)
*
|
2006-04-07 |
2007-10-11 |
Merck Patent Gmbh |
Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
|
US20090203718A1
(en)
*
|
2006-04-13 |
2009-08-13 |
Smithkline Beecham (Cork) Ltd. |
Cancer treatment method
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
KR101367645B1
(ko)
|
2006-04-20 |
2014-02-27 |
얀센 파마슈티카 엔.브이. |
C-fms 키나제의 저해제로서의 복소환식 화합물
|
EP2016070B1
(de)
|
2006-04-20 |
2016-01-13 |
Janssen Pharmaceutica N.V. |
Inhibitoren von c-fms-kinase
|
NZ572299A
(en)
|
2006-05-09 |
2010-07-30 |
Novartis Ag |
Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
US20080119463A1
(en)
*
|
2006-11-16 |
2008-05-22 |
Wyeth |
4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
|
TW200838559A
(en)
*
|
2006-11-29 |
2008-10-01 |
Imclone Systems Inc |
Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
|
AU2007334456A1
(en)
*
|
2006-12-13 |
2008-06-26 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with IGF1R inhibitors
|
WO2008076143A1
(en)
*
|
2006-12-18 |
2008-06-26 |
Osi Pharmaceuticals, Inc. |
Combination of igfr inhibitor and anti-cancer agent
|
EP2120900A2
(de)
|
2007-02-15 |
2009-11-25 |
Novartis AG |
Kombinationen von lb589 mit anderen therapeutischen wirkstoffen zur krebsbehandlung
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
JP2011509290A
(ja)
|
2008-01-11 |
2011-03-24 |
ナトコ ファーマ リミテッド |
抗癌剤としてのピラゾロ[3,4‐d]ピリミジン誘導体
|
WO2009091939A1
(en)
*
|
2008-01-18 |
2009-07-23 |
Osi Pharmaceuticals, Inc. |
Imidazopyrazinol derivatives for the treatment of cancers
|
CN102036953B
(zh)
|
2008-03-24 |
2015-05-06 |
诺华股份有限公司 |
基于芳基磺酰胺的基质金属蛋白酶抑制剂
|
EA019033B1
(ru)
|
2008-03-26 |
2013-12-30 |
Новартис Аг |
Ингибиторы дезацетилазы в, основанные на гидроксамате
|
WO2009143051A1
(en)
*
|
2008-05-19 |
2009-11-26 |
Osi Pharmaceuticals, Inc. |
Substituted imidazopyr-and imidazotri-azines
|
MX2011004824A
(es)
|
2008-11-07 |
2012-01-12 |
Triact Therapeutics Inc |
Uso de derivados de butano catecólico en terapia contra el cáncer.
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
WO2010088335A1
(en)
|
2009-01-29 |
2010-08-05 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(de)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20120064072A1
(en)
|
2009-03-18 |
2012-03-15 |
Maryland Franklin |
Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
|
BRPI1016245A2
(pt)
|
2009-04-20 |
2015-09-01 |
Osi Pharmaceuticals Llc |
Preparação de c-pirazina-metilaminas.
|
WO2010129740A1
(en)
*
|
2009-05-07 |
2010-11-11 |
Osi Pharmaceuticals, Inc. |
Use of osi-906 for treating adrenocortical carcinoma
|
ES2475945T3
(es)
|
2009-06-26 |
2014-07-11 |
Novartis Ag |
Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
IN2012DN01961A
(de)
|
2009-08-17 |
2015-08-21 |
Intellikine Llc |
|
CA2771432A1
(en)
|
2009-08-20 |
2011-02-24 |
Novartis Ag |
Heterocyclic oxime compounds
|
JP2013503129A
(ja)
|
2009-08-26 |
2013-01-31 |
ノバルティス アーゲー |
テトラ−置換ヘテロアリール化合物ならびにmdm2および/またはmdm4モジュレーターとしてのそれらの使用
|
CA2773661A1
(en)
*
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
CN102596951B
(zh)
|
2009-11-04 |
2015-04-15 |
诺华股份有限公司 |
用作mek抑制剂的杂环磺酰胺衍生物
|
EP2504339A1
(de)
*
|
2009-11-25 |
2012-10-03 |
Novartis AG |
Benzolkondensierte 6-gliedrige sauerstoffhaltige heterocyclische derivate bicyclischer heteroaryle
|
US8614239B2
(en)
|
2009-12-08 |
2013-12-24 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
WO2011083124A1
(en)
|
2010-01-05 |
2011-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 receptor antagonists for the treatment or the prevention of pain disorders
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
CA2786800C
(en)
|
2010-01-12 |
2018-02-27 |
Ab Science |
Thiazole and oxazole kinase inhibitors
|
EP2542893A2
(de)
|
2010-03-03 |
2013-01-09 |
OSI Pharmaceuticals, LLC |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
US20110275644A1
(en)
|
2010-03-03 |
2011-11-10 |
Buck Elizabeth A |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011112666A1
(en)
|
2010-03-09 |
2011-09-15 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
WO2012035078A1
(en)
|
2010-09-16 |
2012-03-22 |
Novartis Ag |
17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
|
CN103270026A
(zh)
|
2010-12-21 |
2013-08-28 |
诺瓦提斯公司 |
作为vps34抑制剂的联-杂芳基化合物
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
EP2678016B1
(de)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclische verbindungen und ihre verwendung
|
CN103492390A
(zh)
*
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
CA2834224A1
(en)
|
2011-04-28 |
2012-11-01 |
Novartis Ag |
17.alpha.-hydroxylase/c17,20-lyase inhibitors
|
EP2704571B1
(de)
*
|
2011-05-04 |
2020-04-22 |
Merck Sharp & Dohme Corp. |
Aminopyridinhaltige milz-tyrosinkinase (syk)-hemmer
|
JP2014517004A
(ja)
|
2011-06-09 |
2014-07-17 |
ノバルティス アーゲー |
複素環スルホンアミド誘導体
|
EP2721008B1
(de)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituierte isochinolinone als p53 (mdm2 or mdm4) inhibitoren
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
SG195067A1
(en)
|
2011-06-27 |
2013-12-30 |
Novartis Ag |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
MX339302B
(es)
|
2011-09-15 |
2016-05-19 |
Novartis Ag |
3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
|
KR102063098B1
(ko)
*
|
2011-10-03 |
2020-01-08 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
암 치료를 위한 피롤로피리미딘 화합물
|
CN104080787B
(zh)
|
2011-11-29 |
2016-09-14 |
诺华股份有限公司 |
吡唑并吡咯烷化合物
|
SG11201402237WA
(en)
|
2011-12-22 |
2014-09-26 |
Novartis Ag |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
EP2794594A1
(de)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Chinolinderivate
|
US20140350014A1
(en)
|
2011-12-23 |
2014-11-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
WO2013096049A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140104047A
(ko)
|
2011-12-23 |
2014-08-27 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
ES2894830T3
(es)
|
2012-04-03 |
2022-02-16 |
Novartis Ag |
Productos combinados con inhibidores de tirosina·cinasa y su uso
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN104321325B
(zh)
|
2012-05-24 |
2016-11-16 |
诺华股份有限公司 |
吡咯并吡咯烷酮化合物
|
US9789193B2
(en)
|
2012-06-15 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
EP2882757B1
(de)
|
2012-08-07 |
2016-10-05 |
Janssen Pharmaceutica, N.V. |
Verfahren zur herstellung heterocyclischer esterderivate
|
JP6407504B2
(ja)
|
2012-09-21 |
2018-10-17 |
アログ・ファーマシューティカルズ・インコーポレイテッドArog Pharmaceuticals,Inc. |
恒常的に活性であるリン酸化型flt3キナーゼの阻害方法
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
EP2948451B1
(de)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituierte purinonverbindungen
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
AU2014251038A1
(en)
|
2013-04-08 |
2015-11-26 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
SG11201600028YA
(en)
|
2013-09-22 |
2016-02-26 |
Calitor Sciences Llc |
Substituted aminopyrimidine compounds and methods of use
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
CA2943979A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
CA2944401A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
US10195208B2
(en)
|
2014-07-31 |
2019-02-05 |
Novartis Ag |
Combination therapy
|
US10065937B2
(en)
|
2014-07-31 |
2018-09-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
FLT3 receptor antagonists
|
US9938257B2
(en)
|
2015-09-11 |
2018-04-10 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3254698A1
(de)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3-rezeptor-inhibitoren bei niedriger dosierung zur behandlung von neuropathischem schmerz
|
CA3024012A1
(en)
|
2016-11-02 |
2018-05-11 |
Arog Pharmaceuticals, Inc. |
Crenolanib for treating flt3 mutated proliferative disorders associated mutations
|
KR20200013683A
(ko)
|
2017-05-17 |
2020-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
오피오이드에 의한 통증 치료 개선용 flt3 저해제
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
EP3730483B1
(de)
|
2017-12-21 |
2023-08-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
Klasse von pyrimidinderivaten als kinaseinhibitoren
|
CA3083040A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CA3129665A1
(en)
|
2019-03-21 |
2020-09-24 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
CA3169649A1
(en)
*
|
2020-01-30 |
2021-08-05 |
The Regents Of The University Of California |
Strad-binding agents and uses thereof
|
US11713310B2
(en)
|
2020-07-20 |
2023-08-01 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|